Breaking barriers: How immune therapies are revolutionizing type 1 diabetes treatment

Omanus Gore*

Department of Internal Medicine, Division of Cardiology, 5323 Harry Hines Boulevard, Dallas, Texas, USA

Introduction

Type 1 diabetes (T1D), an autoimmune disorder where the immune system attacks and destroys insulin-producing beta cells in the pancreas, has long been a challenging condition to manage. Patients with T1D must rely on insulin injections or pumps to regulate their blood glucose levels, and even then, they face the constant risk of complications such as heart disease, nerve damage, and kidney failure. However, a new wave of treatments, particularly immune therapies, is offering hope to individuals affected by this condition. These therapies aim not only to manage symptoms but to address the root cause of T1D: the autoimmune attack itself [1].

In T1D, the immune system mistakenly identifies insulin-producing beta cells in the pancreas as foreign invaders and destroys them. This leads to insulin deficiency, which is essential for regulating blood glucose levels. The cause of this immune dysfunction is not entirely understood, but genetic and environmental factors are believed to play a role. The current treatment approach, which involves external insulin administration, can be difficult to perfect and is often accompanied by unpredictable fluctuations in blood glucose. Consequently, researchers have been actively pursuing therapies that can modify the immune system to prevent or even reverse the progression of T1D [2].

Traditionally, treatments for T1D have focused on managing blood glucose through insulin, with little focus on altering the immune response. However, recent advancements in immune therapies have changed this approach, offering the potential to treat the underlying cause of the disease [3].

Immunomodulatory therapies are designed to modify the immune system's behavior without completely suppressing it, as is the case with traditional immunosuppressive treatments. One such therapy involves using monoclonal antibodies, which are laboratory-made molecules that can target specific components of the immune system responsible for attacking beta cells. For example, **teplizumab**, a monoclonal antibody, has shown promising results in delaying the onset of T1D in high-risk individuals and even preserving beta cell function in newly diagnosed patients. By targeting immune cells that attack the pancreas, teplizumab can help prevent or delay the disease's progression [4.

Another exciting approach to immune therapy is **immune tolerization**, where the immune system is "trained" to recognize the beta cells as part of the body and not as foreign invaders. This method aims to induce a state of immune tolerance toward the pancreas, preventing further destruction of beta cells. **DiaPep277**, a peptide-based vaccine, is one example of an immune-tolerizing therapy. It has shown potential in clinical trials by preventing the immune system from attacking the pancreas in people with newly diagnosed T1D [5].

Stem cell therapy is another cutting-edge treatment being explored for T1D. Stem cells have the potential to regenerate damaged tissue, including insulin-producing beta cells. Recent studies have focused on using stem cells to generate new beta cells in patients with T1D. Although still in the experimental phase, this approach could potentially restore insulin production and eliminate the need for lifelong insulin therapy. In some cases, stem cell treatments have also been combined with immunotherapy to prevent the immune system from attacking the newly generated beta cells, offering a comprehensive solution to the problem of beta cell destruction [6].

Gene therapy represents one of the most promising approaches to correcting the immune system's attack on beta cells. By modifying the genes responsible for the autoimmune response, scientists hope to "reprogram" the immune system so that it no longer attacks the pancreas. Researchers are exploring methods such as inserting protective genes into patients' cells or directly modifying the immune system's T cells to prevent them from targeting beta cells. While still in its infancy, gene therapy holds significant promise for the future treatment of T1D, offering the possibility of a permanent, non-invasive solution [7].

The shift toward immune therapies for T1D has led to numerous clinical trials, with encouraging results. The US Food and Drug Administration (FDA) recently granted **breakthrough therapy designation** to teplizumab for its ability to delay the onset of T1D in individuals at high risk. Other immune-modulating drugs are in various stages of clinical testing, with some showing the ability to preserve beta cell function for extended periods, potentially reducing the need for insulin therapy in the long term [8].

***Correspondence to :** **Omanus Gore,** Department of Internal Medicine, Division of Cardiology, 5323 Harry Hines Boulevard, Dallas, Texas, USA. E-mail: omn@gre

***Received:** 30-Aug-2024, Manuscript No. AADY-25-158375; **Editor assigned:** 02- Sep -2024, PreQC No. AADY-25-158375 (PQ); **Reviewed:** 11- Sep -2024, QC No. AADY-25-158375;**Revised:** 16-Sep-2024, Manuscript No. AADY-25-158375; **Published:** 25- Sep -2024, DOI: 10.35841/aady-8.5.221*

***Citation:** Gore O: Breaking barriers: How immune therapies are revolutionizing type 1 diabetes treatment. J Diabetol. 2024;8(5):221*

Stem cell and gene therapies are also being tested, with early trials indicating that these treatments may be able to regenerate beta cells or alter the immune system's behavior in ways that could result in a long-term cure. However, these approaches are still being refined, and more research is necessary to ensure their safety and efficacy.Despite the progress, immune therapies for T1D are not without challenges. The immune system is highly complex, and modulating it to specifically target beta cells while leaving the rest of the immune system intact is no easy task. Additionally, the cost of these therapies can be prohibitive, and large-scale clinical trials are needed to confirm their effectiveness across diverse populations. There is also the issue of long-term safety, as modifying the immune system can sometimes lead to unintended consequences, such as an increased risk of infections or other autoimmune disease [9].

However, the potential for these therapies to transform the lives of individuals with T1D is immense. In the near future, we may see a shift from merely managing the disease to actively preventing or even reversing it. With continued research and development, immune therapies could provide a pathway to a future where Type 1 diabetes is no longer a lifelong burden [10].

Conclusion

Immune therapies represent an exciting frontier in the treatment of Type 1 diabetes. By targeting the autoimmune response that causes the disease, these therapies offer the potential not just to manage symptoms but to halt or even reverse the progression of T1D. While there are still significant hurdles to overcome, the progress made in recent years gives hope that a cure may one day be within reach. As research continues, immune therapies are poised to break the barriers of conventional T1D treatment, offering new hope to those living with this challenging condition.

References

1. Nathan DM. Diabetes: advances in diagnosis and treatment. Jama. 2015;314(10):1052-62.
2. Rother KI. Diabetes treatment—bridging the divide. The New England journal of medicine. 2007;356(15):1499.
3. Bastaki S. Diabetes mellitus and its treatment. International journal of Diabetes and Metabolism. 2005;13(3):111-34.
4. Skyler JS. Diabetes mellitus: pathogenesis and treatment strategies. Journal of medicinal chemistry. 2004;47(17):4113-7.
5. Asche, C., LaFleur, J., & Conner, C. (2011). A review of diabetes treatment adherence and the association with clinical and economic outcomes. *Clinical therapeutics*, *33*(1), 74-109.
6. Suryasa IW, Rodríguez-Gámez M, Koldoris T. Health and treatment of diabetes mellitus. International journal of health sciences. 2021;5(1):1-5.
7. Petrak F, Baumeister H, Skinner TC, Brown A, Holt RI. Depression and diabetes: treatment and health-care delivery. The Lancet Diabetes & Endocrinology. 2015;3(6):472-85.
8. Golbidi S, Alireza Ebadi S, Laher I. Antioxidants in the treatment of diabetes. Current diabetes reviews. 2011;7(2):106-25.
9. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nature reviews drug discovery. 2010 ;9(7):551-9.
10. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes care. 2002;25(1):134-47.

Citation: *Gore O: Breaking barriers: How immune therapies are revolutionizing type 1 diabetes treatment. J Diabetol. 2024;8(5):221*